Last reviewed · How we verify
Myotonic disorder — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Mexitil | MEXILETINE | Boehringer Ingelheim | Antiarrhythmic | 5-hydroxytryptamine receptor 2B | 1985-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Mexitil · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Boehringer Ingelheim · 1 drug in Myotonic disorder
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Myotonic disorder:
- Myotonic disorder treatment updates — RSS
- Myotonic disorder treatment updates — Atom
- Myotonic disorder treatment updates — JSON
Cite this brief
Drug Landscape (2026). Myotonic disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myotonic-disorder. Accessed 2026-06-10.
Related
- Myotonic disorder full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing